跳至主要内容
临床试验/NCT06830564
NCT06830564已完成2 期

The Effect of the Low Dose Nalbuphine Versus Dexmedetomidine on the Prevention of Emergence Agitation After Sevoflurane Anaesthesia in Children Undergoing ENT Surgeries

Ain Shams University1 个研究点 分布在 1 个国家目标入组 126 人开始时间: 2024年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
126
试验地点
1
主要终点
incidence of emergence agitation after sevoflurane anaesthesia

研究概览

简要总结

Low dose nalbuphine versus dexmedetomidine on prevention of emergence agitation in children

详细描述

The incidence of emergence agitation (EA) varies between 18% and 80.

EA occurs most frequently in preschool children during the early stage of emergence from anaesthesia .

It is considered a potentially serious postoperative complication that can result in physical harm and removal of intravenous catheters. As such, EA is a source of dissatisfaction for the parents of paediatric patients and their healthcare providers .

Sevoflurane is an inhalational anaesthetic used widely as a paediatric or outpatient anaesthesia due to its excellent hemodynamic stability and low blood solubility, which allows rapid induction and emergence from general anaesthesia, as well as control of the depth of anaesthesia. However, when sevoflurane is used alone it is associated with a higher incidence of emergence agitation in children. The rapid removal of residual anaesthetics due to low blood solubility of sevoflurane has been suggested to cause emergence agitation in some patients

Nalbuphine is a semi-synthetic, agonist antagonist opioid analgesic agent that acts as a partial agonist at kappa receptors and an antagonist at µ receptors, has minimal side effects, and exhibits a ceiling effect for respiratory depression .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

prospective, randomized, double-blinded, comparative study

入排标准

年龄范围
4 Years 至 10 Years(Child)
性别
All
接受健康志愿者
是

入选标准

  • •Age 4 - 10 years.
  • •Sex: male and female
  • •Patients with ASA classification I and II

排除标准

  • •Refusal of the caregiver to give written informed consent.
  • •History of allergy to the medications used in the study.
  • •psychiatric disorder.
  • •ASA classification III - IV.
  • •Fever, cough, asthma or upper respiratory tract infection.
  • •surgery more than 2 hours
  • •Hearing defect that limits communication.
  • •Neurological disorder .
  • •History of malignant hyperthermia.
  • •surgeries more than 2 hours.

研究组 & 干预措施

Nalbuphine group

Active Comparator

We will give the patient before extubation by15 minute nalbuphine with dose 0.1 mg /kg and we will assess the emergence agitation by delirium score every 15 minutes for half an hour

干预措施: we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure (Drug)

Dexmedetomidine group

Active Comparator

We will give the patient before extubation by 15 minute nalbuphine with dose 0.5 mic /kg and we will assess the emergence agitation by delirium score every 15 minutes for half an hour

干预措施: we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure (Drug)

结局指标

主要结局

incidence of emergence agitation after sevoflurane anaesthesia

时间窗: 6 months

The aim of this study is to prevent 80% of emergence agitation of pediatric undergoing ENT surgeries using sevoflurane as inhalational anaesthesia . low dose nalbuphine versus dexmedetomidine

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验